Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in <i>Braf-</i> Mutant Human Cutaneous Melanoma Cells
Y.N. Vashisht Gopal(AstraZeneca (United Kingdom)), Michael A. Davies(AstraZeneca (United Kingdom))
Cited by 230
Related Papers
A novel AKT3 mutation in melanoma tumours and cell lines
|British Journal of Cancer|2008|267
Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results
|Nature Medicine|2023|75